Mechanisms of Retinal Ganglion Cell Death in Glaucoma
Principal Investigator
Neeraj Agarwal, PhD
University of North Texas Health Science Center
Fort Worth, TX, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$24,203
Active Dates
April 01, 1998 - March 31, 1999
Grant ID
G1998422
Summary
One of the causative events that ultimately leads to blindness in glaucoma is the destruction of ganglion cells in the retina by a process known as apoptosis, or programmed cell death. In order to study how these ganglion cells undergo cell death, we are in the process of establishing a culture of ganglion cells. It is believed that one reason for the apoptosis of ganglion cells could be due to deprivation of oxygen and nutrient supply to these cells. We would like to mimic these conditions in vitro (outside the living organism), by limiting the oxygen and glucose supply to these cultured cells. We would like to study the expression of some “cell saver” genes like Bcl-2 and others like Bax and ICE, which facilitate cell death, under these experimental conditions. We would also like to study, if we could protect the cells from apoptosis by pretreatment with well known antioxidants and ICE inhibitors. These studies could provide very important leads to save the ganglion cells from a pathway leading to its cell death.
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute